BRIEF—Symeres acquires fellow CRO Exemplify BioPharma

Symeres, a Netherlands-based contract research organization (CRO) and contract development manufacturing organization, has acquired Exemplify BioPharma, a USA-based CRO.

The acquisition of the New Jersey firm further strengthens Symeres’ strategic foothold in the USA, where the company already generates about 50% of its revenues.

Exemplify’s functional expertise in process and analytical chemistry and formulation development is seen as a highly synergistic combination with Symeres’ capabilities and service offering.

The deal is Symeres’ second acquisition in the USA this year, following the buy of Organix, an organic chemistry services provider based in the Boston area specialized in lipids addressing the mRNA therapeutics and vaccines market.

Financial terms of the deal have not been disclosed.